DESIGNATED FEDERAL OFFICER (Non-Voting)

Kalyani Bhatt, BS, MS
Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Jess G. Fiedorowicz, MD, PhD
Associate Professor
Departments of Psychiatry, Epidemiology and Internal Medicine
University of Iowa Carver College of Medicine
Iowa City, Iowa

Rajesh Narendran, MD
Attending Psychiatrist
Re:solve Crisis Network
Western Psychiatric Institute and Clinics
Associate Professor in Radiology and Psychiatry
Psychiatric Molecular Imaging Program
University of Pittsburgh
Pittsburgh, Pennsylvania

David Pickar, MD
Adjunct Professor of Psychiatry
Johns Hopkins Medical School
Uniformed Services University of Health Sciences
Gabriel Sciences, LLC
Chevy Chase, Maryland

Robert R. Conley, MD
(Industry Representative)
Global Development Leader
Pain and Core Therapeutics
Team and Distinguished Scholar
Eli Lilly and Company
Indianapolis, Indiana
DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE MEMBERS (Voting)

**Kelly Besco, PharmD, FISMP, CPPS**
*(via telephone)*
Health-System Medication Safety Coordinator
OhioHealth Pharmacy Services
Dublin, Ohio

**Tobias Gerhard, PhD, RPh**
Associate Professor
Rutgers University
Department of Pharmacy Practice and Administration
Ernest Mario School of Pharmacy
New Brunswick, New Jersey

**Almut Winterstein, RPh, PhD, FISPE**
Professor and Crisafi Chair
Pharmaceutical Outcomes & Policy
College of Pharmacy
University of Florida
Gainesville, Florida

TEMPORARY MEMBERS (Voting)

**Dan Budnitz, MD, MPH (CAPT, USPHS)**
Director, Medication Safety Program
Division of Healthcare Quality Promotion
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, Georgia

**Scott S. Emerson, MD, PhD**
Professor of Biostatistics
University Of Washington
Seattle, Washington

**Terry Gillespie**
*(Patient Representative)*
Westmont, Illinois

**Sean Hennessy, PharmD, PhD**
Professor of Epidemiology in Biostatistics and Epidemiology
Department: Biostatistics and Epidemiology
University of Pennsylvania
Philadelphia, Pennsylvania

**Sonia Hernandez-Diaz, MD, DrPH**
Professor of Epidemiology
Department of Epidemiology
Harvard School of Public Health
Boston, Massachusetts

**Jennifer Higgins, PhD**
*(Acting Consumer Representative)*
Director of Strategic Planning and Business Development
Center for Human Development
Springfield, Massachusetts
TEMPORARY MEMBERS (Voting) (cont.)

**Stephen Marder, MD**  
Professor and Director  
Section on Psychosis  
Semel Institute for Neuroscience  
University of California, Los Angeles  
Los Angeles, California

**Glen D. Morgan, PhD**  
Psychologist  
Tobacco Control Research Branch  
Behavioral Research Program  
Division of Cancer Control and Population Sciences  
National Cancer Institute  
National Institutes of Health  
Rockville, Maryland

**Elaine H. Morrato, DrPH, MPH, CPH**  
Associate Dean for Public Health Practice  
Associate Professor Department of Health Systems, Management and Policy  
Colorado School of Public Health  
University of Colorado Anschutz Medical Campus  
Aurora, Colorado

**Ruth M. Parker, MD** *(Acting Chairperson)*  
Professor of Medicine, Pediatrics, and Public Health  
Emory University School of Medicine  
Atlanta, Georgia

**Kenneth A. Perkins, PhD**  
Professor of Psychiatry  
University of Pittsburgh  
Pittsburgh, Pennsylvania

**Rajiv N. Rimal, PhD**  
Professor and Chair  
Department of Prevention and Community Health  
Milken Institute School of Public Health  
George Washington University  
Washington, District of Columbia

**Christanne Roumie, MD, MPH**  
Associate Professor Internal Medicine and Pediatrics  
Institute for Medicine and Public Health  
Vanderbilt University  
Staff Physician  
Veterans Affairs Tennessee Valley Healthcare System  
Nashville, Tennessee
FDA PARTICIPANTS (Non-Voting)

**Mary Thanh Hai, MD**  
Deputy Director  
ODE-II, OND, CDER, FDA

**Sharon Hertz, MD**  
Director  
Division of Anesthesia, Analgesia and Addiction Products (DAAAP)  
Office of Drug Evaluation II (ODE-II)  
Office of New Drugs (OND), CDER, FDA

**Celia Winchell, MD**  
Medical Team Leader  
DAAAP, ODE-II, OND, CDER, FDA

**Judith A. Racoosin, MD, MPH**  
Deputy Director for Safety  
DAAAP, ODE-II, OND, CDER, FDA

**Eugenio Andraça-Carrera, PhD**  
Reviewer, Division of Biometrics VII  
Office of Translational Sciences  
CDER, FDA

**CAPT David Moeny, RPh, MPH, USPHS**  
Acting Director  
Division of Epidemiology II  
Office of Surveillance and Epidemiology  
CDER, FDA